A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Trial Profile

A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Pelareorep (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 03 Mar 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as company has reprioritized clinical plans to focus on later-stage studies.
    • 27 Jan 2017 Planned End Date changed from 1 Jan 2018 to 28 Feb 2018.
    • 27 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top